Latest Healthcare News

Monash IVF has turned down a revised $0.90 per share acquisition proposal from a consortium led by Genesis Capital and WHSP Holdings, citing significant undervaluation and confidence in its new CEO’s growth strategy.

Atomo Diagnostics has responded to ASX queries confirming it first held market-sensitive information after Lumos Diagnostics’ FDA CLIA waiver approval for FebriDx. The company defended its trading halt and capital raise timing, asserting full compliance with ASX Listing Rules.

Fredon, NRW Holdings’ electrical and mechanical arm, has landed contracts worth around $160 million spanning major infrastructure, health, and electric vehicle projects across Australia, with work scheduled through to mid-2028.

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.

Proteomics International Laboratories has slashed a quarter of its workforce and appointed a new CFO amid a strategic pivot to commercial diagnostics, aiming to save over $1 million annually and sharpen execution.

Orthocell has swiftly converted regulatory approval into clinical use with the first Remplir™ surgery completed in a US Department of Defense hospital, marking a key step in its US commercial expansion.

Oneview Healthcare has secured A$12.3 million from its placement and security purchase plan, though the SPP fell well short of its A$2 million target. The company will now seek shareholder approval for the final tranche of its A$19 million raise at the September AGM.

ECP Emerging Growth Limited’s portfolio plunged 19.4% in the March quarter, dragging its net tangible asset value down by nearly 30%, as growth stocks stumbled amid geopolitical tensions and rising rates. The fund added furniture retailer Koala Company and sees value in its resilient holdings despite the rough patch.

Kinatico Ltd has reported a 30% year-on-year rise in SaaS revenue to $5.2 million for Q3 FY26, with EBITDA up 27% amid extended sales cycles and economic uncertainty. The company’s AI-native compliance platform is well positioned for regulatory tailwinds starting July 2026.

BlinkLab has secured A$17.5 million through an oversubscribed placement to fuel regulatory trials and commercial launch of its AI-driven autism and ADHD diagnostic tools.

Audeara has locked in exclusive Australian rights to a customised assistive listening device from ShokzHear, aiming to tackle widespread listening challenges among schoolchildren through government-backed programs.

ReNerve has moved its NervAlign Nerve Guide Matrix into stage 3 of commercial development, a key step toward FDA submission and eventual market entry. This progress supports the company’s ambition to provide surgeons with an alternative to donor nerves for repairing severe peripheral nerve injuries.